Celsion Acquires Microwave Technology Rights for Prostate Cancer Treatment

Celsion Corp. has received the rights to commercialize microwave heat and compression technology for prostate cancer treatment from MMTC, Inc (Princeton, NJ). A system based on the technology has been produced, and enables Celsion to enter the $6 billion U.S. prostate cancer treatment market.

Spencer Volk, Celsion president and CEO, remarked, "We are now pursuing research collaborations to begin the evaluation of our prostate cancer system's safety and efficacy."

Celsion is also planning phase one clinical trials of its breast cancer treatment system that has Investigational Device Exemption (IDE) approval from FDA. The company is finishing phase one clinicals for its nonsurgical outpatient treatment of benign prostatic hyperplasia (BPH).

Celsion Corp. is a research and development company that commercializes medical treatment systems for cancer and BPH using focused heat by microwave technology.